Abstract
Introduction: The role of induction immunosuppression in lung transplantation (LTx) remains controversial, and the efficacy of various agents is uncertain. IL-2 receptor antagonists have potential advantages over conventional cytolytic agents; however, a direct comparison has not been performed in LTx recipients. At our center, both basiliximab (Simulect®) and antithymocyte globulin (ATGAM®) have been used for induction immunosuppression. Our purpose was to determine the impact of these agents on biopsy-proven acute rejection in the first three months after LTx.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
